1. Critical Reviews in Oncology / Hematology
Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials 
Giuseppe Lombardi, Ardi Pambuku, Luisa Bellu, Miriam Farina, Alessandro Della Puppa, Luca Denaro, Vittorina Zagonel 
Critical Reviews in Oncology / Hematology 
Volume 111, Pages (March 2017)
DOI: /j.critrevonc
Copyright © 2017 Elsevier B.V. Terms and Conditions

2. Fig. 1
The PRISMA flowchart summarizing the process for the identification of the eligible studies.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2017 Elsevier B.V. Terms and Conditions

3. Fig. 2
Hazard Ratios for overall survival (A) and progression-free survival (B). ES: effect size (HR); CI: confidence interval; W: weight; Sig: statistical significance; N: number of patients; ced: cediranib; lom: lomustine; cil: cilengitide; intCil: intensive cilengitide; bev: bevacizumab.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2017 Elsevier B.V. Terms and Conditions

4. Fig. 3
Funnel plot scatter plots of antiangiogenic drug effects estimated from individual studies (horizontal axis) against the study size (vertical axis). The symmetric inverted funnel shape and the fill and trim analysis (result in black) suggest that publication bias in unlikely. A: effect size (HR) for overall survival; B: effect size (HR) for progression-free survival.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2017 Elsevier B.V. Terms and Conditions

5. Fig. 4
Overall survival by subgroups: (A) Bevacizumab or other antiangiogenic drugs; (B) Antiangiogenic drugs as first or second-line treatment; (C) Antiangiogenic drugs alone or in association to cytotoxic treatment; (D) Bevacizumab alone or in association to cytotoxic drugs; (E) Bevacizumab as first or second-line treatment. ES: effect size (HR for OS); CI: confidence interval; W: weight; Sig: statistical significance; N: number of patients; ced: cediranib; lom: lomustine; cil: cilengitide; intCil: intensive cilengitide; bev: bevacizumab.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2017 Elsevier B.V. Terms and Conditions

6. Fig. 5
Progression-free survival by subgroups: (A) Bevacizumab or other antiangiogenic drugs; (B) Antiangiogenic drugs as first or second-line treatment; (C) Antiangiogenic drugs alone or in association to cytotoxic treatment; (D) Bevacizumab alone or in association to cytotoxic drugs; (E) Bevacizumab as first or second-line treatment; (F) Antiangiogenic drugs (except for bevacizumab) alone or in association to cytotoxic treatment. ES: effect size (HR for OS); CI: confidence interval; W: weight; Sig: statistical significance; N: number of patients; ced: cediranib; lom: lomustine; cil: cilengitide; intCil: intensive cilengitide; bev: bevacizumab.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2017 Elsevier B.V. Terms and Conditions